IL290045A - Deuterium-converted mk2 pathway inhibitors and methods of using them - Google Patents
Deuterium-converted mk2 pathway inhibitors and methods of using themInfo
- Publication number
- IL290045A IL290045A IL290045A IL29004522A IL290045A IL 290045 A IL290045 A IL 290045A IL 290045 A IL290045 A IL 290045A IL 29004522 A IL29004522 A IL 29004522A IL 290045 A IL290045 A IL 290045A
- Authority
- IL
- Israel
- Prior art keywords
- deuterated
- methods
- same
- pathway inhibitors
- pathway
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290045A true IL290045A (en) | 2022-03-01 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290045A IL290045A (en) | 2019-07-31 | 2022-01-23 | Deuterium-converted mk2 pathway inhibitors and methods of using them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12403141B2 (OSRAM) |
| EP (1) | EP4003344A4 (OSRAM) |
| JP (1) | JP2022542434A (OSRAM) |
| KR (1) | KR20220041180A (OSRAM) |
| CN (1) | CN114206339A (OSRAM) |
| AU (1) | AU2020319879A1 (OSRAM) |
| BR (1) | BR112022001324A2 (OSRAM) |
| CA (1) | CA3149304A1 (OSRAM) |
| IL (1) | IL290045A (OSRAM) |
| MX (1) | MX2022001151A (OSRAM) |
| PH (1) | PH12022550029A1 (OSRAM) |
| WO (1) | WO2021022186A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022019349A2 (pt) * | 2020-03-27 | 2022-11-16 | Aclaris Therapeutics Inc | Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto |
| IL307187A (en) | 2021-03-31 | 2023-11-01 | Xinthera Inc | MK2 inhibitors and their uses |
| KR20240035830A (ko) | 2021-07-09 | 2024-03-18 | 신테라, 인크. | 피리디논 mk2 저해제 및 이의 용도 |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TWI836822B (zh) * | 2021-12-29 | 2024-03-21 | 大陸商上海美悦生物科技發展有限公司 | p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023134764A1 (zh) | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
| US20230286950A1 (en) * | 2022-02-04 | 2023-09-14 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| WO2023165554A1 (zh) * | 2022-03-03 | 2023-09-07 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
| WO2024149359A1 (zh) * | 2023-01-13 | 2024-07-18 | 上海美悦生物科技发展有限公司 | 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途 |
| US20260115177A1 (en) * | 2023-01-13 | 2026-04-30 | Poolbeg Pharma (UK) Limited | Medicinal products and methods for the alleviation of cancer immunothera-py-associated cytokine release syndrome |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
| SG176010A1 (en) * | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| US8575348B2 (en) * | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| CA2819889C (en) * | 2010-12-06 | 2020-12-15 | Confluence Life Sciences, Inc. | Substituted pyridinone-pyridinyl compounds |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| CA2917344C (en) * | 2013-06-07 | 2021-09-07 | Confluence Life Sciences, Inc. | Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| CZ2015601A3 (cs) * | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| CN111727042A (zh) * | 2017-12-06 | 2020-09-29 | 仁新医药私人有限公司 | 微管蛋白抑制剂 |
| EP4114411A4 (en) | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
-
2020
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt not_active IP Right Cessation
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en not_active Ceased
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja not_active Ceased
- 2020-07-31 PH PH1/2022/550029A patent/PH12022550029A1/en unknown
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en not_active Abandoned
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko active Pending
- 2020-07-31 US US17/630,414 patent/US12403141B2/en active Active
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4003344A1 (en) | 2022-06-01 |
| US20220288070A1 (en) | 2022-09-15 |
| AU2020319879A1 (en) | 2022-02-03 |
| CN114206339A (zh) | 2022-03-18 |
| PH12022550029A1 (en) | 2023-02-27 |
| BR112022001324A2 (pt) | 2022-03-22 |
| KR20220041180A (ko) | 2022-03-31 |
| WO2021022186A1 (en) | 2021-02-04 |
| CA3149304A1 (en) | 2021-02-04 |
| US12403141B2 (en) | 2025-09-02 |
| MX2022001151A (es) | 2022-02-22 |
| EP4003344A4 (en) | 2023-07-26 |
| JP2022542434A (ja) | 2022-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290399A (en) | kras g12c inhibitors and methods of using them | |
| IL288381A (en) | Tead inhibitors and their uses | |
| IL288384A (en) | Tead inhibitors and their uses | |
| IL282487B1 (en) | Tyk2 inhibitors and their use | |
| IL272512A (en) | KRAS G12C inhibitors and methods of using them | |
| IL279276A (en) | ERK inhibitor and use thereof | |
| IL276687A (en) | Trialkyne coupling agents and methods of using them | |
| SG11202105769XA (en) | Inhibitors of apol1 and methods of using same | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL307187A (en) | MK2 inhibitors and their uses | |
| IL282090B2 (en) | TYK2 inhibitors and their uses | |
| SG10201913562VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| EP3596085A4 (en) | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES | |
| IL289127A (en) | ppm1a inhibitors and methods of using them | |
| IL280924A (en) | Arginase inhibitors and methods of using them | |
| IL286149A (en) | Caspase inhibitors and methods of using them | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| HK40070182A (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
| IL282671A (en) | Therapeutic methods and compositions | |
| SG11202011549RA (en) | Topical formulations of dgat1 inhibitors and their methods of use | |
| GB201908884D0 (en) | Inhibitors and use |